TrialInvestigational new drugs2015

Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer.

Khanh Do et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.